Effects of imidazoline antihypertensive drugs on sympathetic tone and noradrenaline release in the prefrontal cortex
Authors:
- 1 September 2001
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 134 (2) , 295-304
Abstract
The aim of the present study was to compare the effects of the centrally acting antihypertensive drugs rilmenidine, moxonidine, clonidine and guanabenz on sympathetic tone with their effects on noradrenaline release in the cerebral cortex. In particular, the hypothesis was tested that rilmenidine and moxonidine, due to their high affinity for sympatho‐inhibitory imidazoline I1 receptors and low affinity for α2‐adrenoceptors, lower sympathetic tone without causing an α2‐adrenoceptor‐mediated inhibition of cerebrocortical noradrenaline release. In rats anaesthetized with urethane, blood pressure and heart rate were measured and the concentration of noradrenaline in arterial blood plasma was determined. The release of noradrenaline in the medial prefrontal cortex was estimated by microdialysis. Intravenous administration of rilmenidine (30, 100, 300 and 1000 μg kg−1), moxonidine (10, 30, 100 and 300 μg kg−1), clonidine (1, 3, 10 and 30 μg kg−1) and guanabenz (1, 3, 10 and 30 μg kg−1) led to dose‐dependent hypotension and bradycardia; the plasma noradrenaline concentration also decreased. After the two highest doses, all four drugs lowered noradrenaline release in the prefrontal cortex. At doses eliciting equal hypotensive and sympatho‐inhibitory responses, rilmenidine and moxonidine inhibited cerebral cortical noradrenaline release at least as much as clonidine and guanabenz. The results show that rilmenidine and moxonidine lower cerebrocortical noradrenaline release at doses similar to those which cause sympatho‐inhibition. This effect was probably due to an α2‐adrenoceptor‐mediated inhibition of the firing of locus coeruleus neurons and, in addition, to presynaptic inhibition of noradrenaline release at the level of the axon terminals in the cortex. The results argue against the hypothesis that rilmenidine and moxonidine, due to their selectivity for sympatho‐inhibitory I1 imidazoline receptors, do not suppress noradrenergic neurons in the central nervous system. British Journal of Pharmacology (2001) 134, 295–304; doi:10.1038/sj.bjp.0704237Keywords
This publication has 58 references indexed in Scilit:
- Drugs Acting on Imidazoline ReceptorsDrugs, 1999
- Modulation of catecholamine release by α2-adrenoceptors and I1-imidazoline receptors in rat brainBrain Research, 1997
- Antisense technology reveals the alpha2A adrenoceptor to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat.Journal of Clinical Investigation, 1996
- Distribution of ?2C-adrenergic receptor-like immunoreactivity in the rat central nervous systemJournal of Comparative Neurology, 1996
- Human brain imidazoline receptors: further characterization with [3H]clonidineEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- A Hypnotic Response to Dexmedetomidine, an α2 Agonist, Is Mediated in the Locus Coerüleus in RatsAnesthesiology, 1992
- Imidazole binding sites in rabbit kidney and forebrain membranesJournal of Autonomic Pharmacology, 1991
- A multicenter double-blind comparative study of rilmenidine and clonidine in 333 hypertensive patientsThe American Journal of Cardiology, 1988
- Comparison of Moxonidine and Clonidine HCl in Treating Patients With HypertensionThe Journal of Clinical Pharmacology, 1987
- Extension of Sample Sizes and Percentage Points for Significance Tests of Outlying ObservationsTechnometrics, 1972